Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andre Goy

Showing results (141-150 of 164) with videos related to

Pageof 17
Sort By:
Leukemia & Lymphoma|July 16, 2021
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignanciesGraham P Collins, Tracy N Clevenger, Kathleen A Burke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2020
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumLoretta J Nastoupil, Michael D Jain, Lei Feng, et al.
Blood|September 8, 2016
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experienceAnthony R Mato, Chadi Nabhan, Paul M Barr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2021
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare)Anthony R Mato, Matthew S Davids, Jeff Sharman, et al.
Blood|October 29, 2025
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3Tom van Meerten, Marie José Kersten, Gloria Iacoboni, et al.
Transplantation and Cellular Therapy|April 6, 2026
Outcomes of Salvage Therapy After Early-Line CD19 CAR-T Failure in Large B-Cell LymphomaSilvia Escribano Serrat, Andrew Ip, Jaime Sanz, et al.
The New England Journal of Medicine|June 21, 2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphomaMichael L Wang, Simon Rule, Peter Martin, et al.
The New England Journal of Medicine|June 3, 2022
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell LymphomaMichael L Wang, Wojciech Jurczak, Mats Jerkeman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2023
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T ConsortiumYucai Wang, Preetesh Jain, Frederick L Locke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptorJames N Kochenderfer, Mark E Dudley, Sadik H Kassim, et al.
Pageof 17

Showing results (141-150 of 164) with videos related to

Sort By:
Pageof 17
Leukemia & Lymphoma|July 16, 2021
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignanciesGraham P Collins, Tracy N Clevenger, Kathleen A Burke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2020
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumLoretta J Nastoupil, Michael D Jain, Lei Feng, et al.
Blood|September 8, 2016
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experienceAnthony R Mato, Chadi Nabhan, Paul M Barr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2021
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare)Anthony R Mato, Matthew S Davids, Jeff Sharman, et al.
Blood|October 29, 2025
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3Tom van Meerten, Marie José Kersten, Gloria Iacoboni, et al.
Transplantation and Cellular Therapy|April 6, 2026
Outcomes of Salvage Therapy After Early-Line CD19 CAR-T Failure in Large B-Cell LymphomaSilvia Escribano Serrat, Andrew Ip, Jaime Sanz, et al.
The New England Journal of Medicine|June 21, 2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphomaMichael L Wang, Simon Rule, Peter Martin, et al.
The New England Journal of Medicine|June 3, 2022
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell LymphomaMichael L Wang, Wojciech Jurczak, Mats Jerkeman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2023
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T ConsortiumYucai Wang, Preetesh Jain, Frederick L Locke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptorJames N Kochenderfer, Mark E Dudley, Sadik H Kassim, et al.
Pageof 17